Asymmetric Binding to NS5A by Daclatasvir (BMS-790052) and Analogs Suggests Two Novel Modes of HCV Inhibition

Symmetric, dimeric daclatasvir (BMS-790052) is the clinical lead for a class of picomolar inhibitors of HCV replication. While specific, resistance-bearing mutations at positions 31 and 93 of domain I strongly suggest the viral NS5A as target, structural mechanism(s) for the drugs’ activities and re...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of medicinal chemistry 2014-12, Vol.57 (23), p.10031-10043
Hauptverfasser:	Nettles, James H, Stanton, Richard A, Broyde, Joshua, Amblard, Franck, Zhang, Hongwang, Zhou, Longhu, Shi, Junxing, McBrayer, Tamara R, Whitaker, Tony, Coats, Steven J, Kohler, James J, Schinazi, Raymond F
Format:	Artikel
Sprache:	eng
Schlagworte:	Amino Acid Sequence Antiviral Agents - pharmacology Carbamates Hepacivirus - drug effects Imidazoles - metabolism Imidazoles - pharmacology Molecular Docking Simulation Pyrrolidines Sequence Alignment Structure-Activity Relationship Valine - analogs & derivatives Viral Nonstructural Proteins - antagonists & inhibitors Viral Nonstructural Proteins - metabolism Virus Replication - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!